Viral Vector Manufacturing Market by Product Type, Distribution Channel, End User 2024-2032

1
Global Viral Vector Manufacturing Market Research
and Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Viral Vector Manufacturing Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2024-2032," the global viral vector
  manufacturing market size reached US 1,200.1
  Million in 2023.
• A viral vector is a tool used to deliver genetic
  material into cells. This process is performed
  inside a living organism (in vivo) or in cell
  culture (in vitro). It is widely used in gene and
  cell therapy to replace defective genes with
  functional genes.
• Besides this, viral vectors are also utilized to
  treat different diseases, such as heart defects,
  metabolic diseases, neurodegenerative disorders,
  and oncolytic therapies, to target and kill tumor
  cells. In recent years, there has been a
  significant rise in viral vector manufacturing
  due to the rising prevalence of genetic
  disorders.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/viral-vector-manufactur
  ing-market/requestsample

4
Report Description

• Global Viral Vector Manufacturing Market Trends
• The market is primarily driven by the rising
  number of cancer patients across the globe as
  viral vectors are used in suicide gene therapy,
  oncolytic virotherapy, anti-angiogenesis, and
  therapeutic gene vaccines to treat a wide range
  of cancers. In addition, the increasing number of
  clinical studies undertaken on viral vectors is
  contributing to the market growth. Besides this,
  as viral vectors are efficient carriers of
  virus-disabling sequences, they are widely used
  to deliver HIV-inhibiting transgenes to human
  hematopoietic stem cells (HSCs).
• This, coupled with the rising utilization of
  viral vectors in novel drug delivery, is
  positively influencing the market growth.
  Furthermore, the introduction of advanced
  therapies, the rising number of gene
  therapy-based research and development (RD)
  activities, and the increasing manufacturing
  capacities of key players are anticipated to
  propel the market growth.
• Looking forward, IMARC Group expects the market
  value to reach US 7,681.6 Million by 2032,
  exhibiting a CAGR of 22.4 during 2024-2032.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/viral-vector-manufactur
  ing-market

5
Report Segmentation

• Breakup by Type
• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others
•  
• Breakup by Disease
• Cancer
• Genetic Disorders
• Infectious Diseases
• Others
• Breakup by Application
• Gene Therapy

6
Report Segmentation

• Vaccinology
• Breakup by End User
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Cognate BioServices Inc. (Charles River
  Laboratories International Inc.)
• F. Hoffmann-La Roche AG
• FinVector Oy
• FUJIFILM Holdings Corporation
• Kaneka Eurogentec S.A. (Kaneka Corporation)
• Lonza Group AG
• Merck KGaA
• Oxford Biomedica plc
• REGENXBIO Inc.
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• uniQure N.V.

8
Key Questions Answered in the Report
9
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Viral Vector
  Manufacturing Market    5.1    Market Overview 
    5.2    Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by  Type    6.1  
   Adenoviral Vectors        6.1.1 Market Trends 
        6.1.2 Market Forecast    6.2  
   Adeno-associated Viral Vectors        6.2.1
  Market Trends        6.2.2 Market Forecast   
  6.3    Lentiviral Vectors        6.3.1 Market
  Trends        6.3.2 Market Forecast       

10
Table of Contents

•     6.4    Retroviral Vectors        6.4.1
  Market Trends        6.4.2 Market Forecast   
  6.5    Others        6.5.1 Market Trends       
  6.5.2 Market Forecast7   Market Breakup by
  Disease    7.1    Cancer        7.1.1 Market
  Trends        7.1.2 Market Forecast    7.2  
   Genetic Disorders        7.2.1 Market Trends 
        7.2.2 Market Forecast    7.3    Infectious
  Diseases        7.3.1 Market Trends       
  7.3.2 Market Forecast    7.4    Others       
  7.4.1 Market Trends        7.4.2 Market
  Forecast8   Market Breakup by Application   
  8.1    Gene Therapy        8.1.1 Market Trends 
        8.1.2 Market Forecast    8.2  
   Vaccinology        8.2.1 Market Trends       
  8.2.2 Market Forecast
• 9   Market Breakup by End User    9.1  
   Pharmaceutical and Biopharmaceutical Companies 
        9.1.1 Market Trends        9.1.2 Market
  Forecast
• For more information, visit https//www.imarcgrou
  p.com/viral-vector-manufacturing-market/toc

11
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

12
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com